m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02412)
Name
TRISMETHOXYRESVERATROL
Synonyms
22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; TRISMETHOXYRESVERATROL; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene
    Click to Show/Hide
Status
Investigative
Structure
Formula
C17H18O3
InChI
1S/C17H18O3/c1-18-15-8-6-13(7-9-15)4-5-14-10-16(19-2)12-17(11-14)20-3/h4-12H,1-3H3/b5-4+
InChIKey
GDHNBPHYVRHYCC-SNAWJCMRSA-N
PubChem CID
5388063
TTD Drug ID
D0O9NE
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 1B1 (CYP1B1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for TRISMETHOXYRESVERATROL. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of TRISMETHOXYRESVERATROL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for TRISMETHOXYRESVERATROL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TRISMETHOXYRESVERATROL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). [2], [3]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for TRISMETHOXYRESVERATROL. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of TRISMETHOXYRESVERATROL through regulating the expression of P-glycoprotein 1 (ABCB1). [4], [5]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for TRISMETHOXYRESVERATROL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TRISMETHOXYRESVERATROL through regulating the expression of P-glycoprotein 1 (ABCB1). [5], [6]
References
Ref 1 LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene. 2020 Jul;39(31):5358-5372. doi: 10.1038/s41388-020-1338-9. Epub 2020 Jun 23.
Ref 2 Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4. doi: 10.1021/jm010298j.
Ref 3 METTL3 contributes to renal ischemia-reperfusion injury by regulating Foxd1 methylation. Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F839-F847. doi: 10.1152/ajprenal.00222.2020. Epub 2020 Sep 21.
Ref 4 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 5 Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. doi: 10.1021/jm060253o.
Ref 6 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.